Turbulent biotech markets on both sides of the pond have come at a cost to many smaller stocks including RedX Pharma (REDX). Its shares are down over a half since January and yet it is still making big leaps towards commercialising or partnering its drugs, which fall into three different therapeutic areas: oncology, immunology and antibiotics.
IC TIP:
Buy
at
27p
Since January RedX has moved several assets into the clinic and now has entered into a supply agreement with Welsh formulation group Quay Pharma, which will provide the right quantity of drugs for the first human study into a new cancer treatment, due to begin in January 2017.
